Many of you inquired about the recent volatility in the technology sector and, although several reasons exist, one of them was a fairly large sell-off in the biotechnology stocks. I view it as simple profit taking and expect continued growth here.
Let’s look at how Arizona is doing in this regard. . .
The Business Journal recently ran an article written by Angela Gonzales outlining the state of our bioscience industry. It’s impressive.
“Arizona’s bioscience industry now has 106,846 jobs generating an average wage of $62,775, which is 39% higher than the private-sector average, according to the Flinn Foundation’s Bioscience Roadmap released April 8th.
Total revenue generated by the state’s bioscience industry is about $14 billion, excluding hospitals. With hospitals included, that number tops $36 billion.
Mayo Clinic, Arizona State University and the city of Phoenix are working together to develop a 225-acre biomedical corridor just north of the Mayo Clinic Hospital in Phoenix.
KUD International has submitted an application with the Arizona State Land Department to buy or lease that property.”
To learn more about the development of Arizona as a global bioscience center, please visit:
It seems likely that the biotechnology sector will continue to attract investors and I’m glad to see how Arizona may benefit too.
Until next week,
Susan R. Linkous
Investing in any sector can bring added risk and volatility over a more diversified portfolio so be sure and seek advice before investing. This is opinion only and should not be construed as specific investment advice.
Investment advice offered through
The Linkous Group, Ltd.
A Registered Investment Advisor
Securities offered through LPL Financial
Member FINRA and SIPC
LPL Financial and The Linkous Group, Ltd. are separate entities.